Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser and Light-Sensitive drug aim to zap prostate cancer without surgery

NCT ID NCT06807359

Recruiting now Disease control Sponsor: SpectraCure AB Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment for men with localized prostate cancer. It uses a light-sensitive drug called verteporfin, which is injected into the bloodstream and then activated by laser light delivered through thin fibers placed into the prostate. The goal is to destroy cancer cells while minimizing damage to healthy tissue. The study will enroll 43 participants and follow them for up to 3 years to check safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
verteporfin (a light-activated drug)
What this could lead to
If successful, this could offer a less invasive treatment option for localized prostate cancer that targets tumors precisely and reduces side effects compared to surgery or radiation.
What could go wrong
This is an early-phase trial with only 43 participants, so results may not apply to all patients. The treatment requires general anesthesia and carries risks like damage to nearby tissues or side effects from the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Klinik für Urologie, Universitätsklinikum Köln

    RECRUITING

    Cologne, 50937, Germany

  • Klinik und Poliklinik für Urologie, Universitätsmedizin Rostock

    RECRUITING

    Rostock, Germany

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.